Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Reportedly, Merck Expected To Close $11B Deal With Blood-Related Disorder Therapeutics Firm Acceleron Pharma

By John F. Heerdink, Jr.

Reportedly, Merck & Co., Inc. (MRK) is in advanced talks to acquire drugmaker Cambridge, Massachusetts-based, Acceleron Pharma Inc (XLRN) .  Acceleron is focused on the discovery, development, and commercialization of therapeutics to treat blood-related disorders. 

As per a Bloomberg report, Acceleron was in talks to be acquired for more than $11 billion. It was earlier reported that several drugmakers including Bristol-Myers Squibb Co, Merck’s rival that owns 11.5% of Acceleron’s stock, were viewed as potential suitors. Acceleron currently earns royalties from sales of a drug to treat two blood-related disorders, Reblozyl and is developing another treatment for a type of high blood pressure that affects the lungs.

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

(Read Original Story: UPDATE 2-Merck in advanced talks to buy Acceleron Pharma - WSJ in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us